GlobeNewswire by notified

Nexstim Receives an NBS System Order from a Customer in Europe

Share

Nexstim Receives an NBS System Order from a Customer in Europe

Press release, Helsinki, 25August 2022 at 10AM (EET)

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") has received an NBS 5 System order from a customer in Europe. The customer is a new user of the Nexstim NBS system, acquiring the system to enable future neuroscience projects.

Nexstim’s SmartFocus® nTMS (navigated transcranial magnetic stimulation) technology enables accurate and personalized stimulation, considering the unique shape and conductivity of each patient’s brain. Nexstim’s NBS (Navigated Brain Stimulation) system is used, for example, in planning neurosurgery and in the case of this customer enables neuroscience studies where the stimulation needs to be targeted individually to the brain, reproducing the pulse delivery reliably for diagnosis.

This specific NBS system also includes the software of an NBT® (Navigated Brain Therapy) system, allowing it to also be used for the treatment of major depression and chronic neuropathic pain.

Mikko Karvinen, CEO of Nexstim, comments: Nexstim has been actively working as a partner in TMS-EEG development. TMS-evoked EEG responses are sensitive to even the smallest shifts in stimulation location. While allowing highly location-specific data to be gathered, this also makes a reliable, precise and accurate navigation solution imperative for TMS-EEG measurements and even more so when studies require repeatability and reproducibility.We are very happy to see that our development work at Nexstim results in enabling new customers to use our world-leading technology in their neuroscience research projects.

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit www.nexstim.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Mohawk Industries, Inc. Invites You to Join the Third Quarter 2022 Earnings Conference Call5.10.2022 22:01:23 CEST | Press release

CALHOUN, Ga., Oct. 05, 2022 (GLOBE NEWSWIRE) -- In conjunction with Mohawk Industries, Inc. (NYSE: MHK) Third Quarter 2022 earnings release on Thursday October 27, 2022, you are invited to listen to the conference call that will be broadcast live on Friday October 28, 2022 at 11:00 am ET. What:Mohawk Industries, Inc. 3rd Quarter 2022 Earnings CallWhen:October 28, 202211:00 am ETWhere:www.mohawkind.comSelect Investor InformationHow:Live over the Internet – Simply log on to the web at the address above orRegister for the conference call at https://dpregister.com/sreg/10171853/f4b0080751Live Conference Call:Dial 1-833-630-1962 (US/Canada)Dial 1-412-317-1843 (Int’l) Mohawk Industries is the leading global flooring manufacturer that creates products to enhance residential and commercial spaces around the world. Mohawk’s vertically integrated manufacturing and distribution processes provide competitive advantages in the production of carpet, rugs, ceramic tile, laminate, wood, stone and viny

REPURCHASE OF SHARES5.10.2022 20:00:00 CEST | Press release

REPURCHASE OF SHARES Amsterdam, the Netherlands - Flow Traders N.V. (“Flow Traders”) (Euronext: FLOW) has repurchased 54,950of its own shares in the period from 29September 2022 up to and including 5October 2022 at an average price of €19.28. This is in accordance with the share buyback programme announced on 22 July 2022. The consideration of this purchase was €1.1 million. The total number of shares purchased under this programme to date is 337,152 shares at an average price of €19.43 for a total consideration of €6.6 million. 3,127,247 shares were held in treasury as at 5 October 2022. Contact Details Flow Traders N.V. Jonathan Berger / Investor Relations Officer Phone: +31 20 7996799 Email: investor.relations@flowtraders.com About Flow Traders Flow Traders is a leading global financial technology-enabled liquidity provider in financial products, historically specialized in Exchange Traded Products (ETPs), now expanding into other asset classes. Flow Traders ensures the provision of

Dovre's Suvic Oy has signed a contract for the foundation construction of two new wind farms5.10.2022 17:00:00 CEST | Press release

Dovre Group Plc Press release October 5, 2022 at 6 pm Dovre's Suvic Oy has signed a contract for the foundation construction of two new wind farms Suvic has signed a design and construction agreement for constructing the foundations for two new wind farms in Ostrobothnia in the municipality of Ii. The new wind farms will be called Isokangas and Palokangas. The design work will start by the end of 2022 and the construction work will commence in the spring of 2023. The owner of the project is Exilion Tuuli, which is an investment company owned by Elo, The State Pension Fund of Finland and Veritas. Isokangas and Palokangas will together have 17 windmills with a total capacity of 100 MW. "We are very happy to start cooperation with a new Finnish customer Exilion Oy", states Suvic Oy's CEO and Chairman of the Board Mr. Ville Vesanen. Additional information: Suvic Oy Ville Vesanen CEO Tel. +358 44 328 9928 vve@suvic.fi, www.suvic.fi Suvic Oy is a Finnish construction company founded in 2017

Evaxion welcomes Per Norlén as new CEO.5.10.2022 14:32:40 CEST | Press release

COPENHAGEN, Denmark, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announces that its new Chief Executive Officer (CEO) Per Norlén has joined the company on October 3rd. Dr. Norlén is a board-certified physician and associate professor with more than 20 years in the biotech sector, of which the last decade has been in executive leadership roles. He brings a wealth of experience from being CEO of listed drug development companies. He has a proven business development track record, including major out-licensing deals with biotech and Pharma. “Evaxion has emerged from being an under-the-radar start-up to becoming a clinical stage biotech company leading the development of tailored cancer immunotherapies, individually designed for each patient. I am convinced that Evaxion is on to something extremely important that holds the potential to

UPM inaugurates its new deep sea pulp terminal in the Port of Montevideo5.10.2022 14:00:00 CEST | Press release

(UPM, Helsinki, 5 October 2022 at 15:00 EEST) – UPM inaugurates today its new pulp terminal in the port of Montevideo, Uruguay. This investment of approximately USD 280 million is a fundamental part of UPM’s USD 3.47 billion growth investment in Uruguay that includes a state-of-the-art pulp mill in Paso de los Toros, new eucalyptus tree nursery as well as local community investments in Paso de los Toros. “This is a significant milestone in our growth project in Uruguay. The new pulp terminal with direct connections from the new pulp mill and to the global markets plays a key role in the growth and competitiveness of UPM’s pulp business,” says UPM President and CEO JussiPesonen. “The public infrastructure investments to the deep sea port and railway improve the competitiveness of all export sectors in Uruguay.” The new pulp terminal is located in the newly developed deep sea port in Montevideo, and it will have a direct rail connection to the new UPM Paso de los Toros mill. In the futur